SCHEMBL4937484

SCHEMBL4937484

CC1CCCCN1c1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 11/20 0.53
GPR55 Q9Y2T6 4/20 0.48
CNR1 P21554 1/20 0.48
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SLC6A5 Q9Y345 1/20 0.44
USP2 O75604 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933835 0.86 SLC6A9 (0.70) SLC6A9GPR55CNR1MAPTALDH1A1
SCHEMBL4930270 0.82 SMN1; SMN2 (0.59) SLC6A9GPR55MAPTALDH1A1HTT
SCHEMBL4934646 0.80 SLC6A9 (0.72) SLC6A9GPR55CNR1MAPTALDH1A1
SCHEMBL4939424 0.79 SLC6A9 (0.56) SLC6A9GPR55CNR1MAPTALDH1A1
SCHEMBL6500795 0.79 SLC6A9 (0.69) SLC6A9SLC6A5
SCHEMBL4938526 0.79 SLC6A9 (0.58) SLC6A9GPR55CNR1MAPTALDH1A1
SCHEMBL8256322 0.78 SMN1; SMN2 (0.55) SLC6A9GPR55MAPTALDH1A1HTT
SCHEMBL4938129 0.77 GFER (0.54) SLC6A9HTTLMNATSHRSMN1; SMN2
SCHEMBL4939869 0.76 GPR55 (0.59) SLC6A9GPR55CNR1MAPTALDH1A1
SCHEMBL3924706 0.76 SLC6A9 (0.70) SLC6A9ALDH1A1SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors GLAXO GROUP LIMITED 2008-04-17 US disclosed
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors GLAXO GROUP LIMITED 2008-04-17 US disclosed
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors GLAXO GROUP LIMITED 2008-04-17 US disclosed
EP-1856077-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-21 EP disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors SLC6A7, SLC6A5, SLC1A2 SLC6A9 22/4885GPR55 395/4885CNR1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.